Darifenacin indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency. 

Overactive Bladder

Urinary Incontinence

The recommended starting dose of darifenacin extended-release tablets is 7.5 mg once daily. Based upon individual response, the dose may be increased to 15 mg once daily, as early as two weeks after starting therapy. 

The following adverse reactions are reported with the use of darifenacin-

• Dry mouth
• Constipation
• Dyspepsia
• Abdominal pain
• Nausea
• Diarrhea
• Urinary tract infection
• Dizziness
• Asthenia
• Dry eyes

Dry Mouth	Constipation	Dyspepsia	Abdominal Pain
Nausea	Diarrhea	Canine Urinary Tract Infection	Asthenia

• Because of the risk of urinary retention, darifenacin extended-release tablets should be used with caution in patients with clinically significant bladder outflow obstruction.
• Because of the risk of gastric retention, Darifenacin should be used with caution in patients with gastrointestinal obstructive disorders. Darifenacin, like other anticholinergic drugs, can reduce gastrointestinal motility and should be used with caution in patients with severe constipation, ulcerative colitis, or myasthenia gravis.
• Darifenacin should be used with caution and only when the potential benefits outweigh the risks in patients with narrow-angle glaucoma.
• For patients with mild hepatic impairment, there are no dosing adjustments. For patients with moderate hepatic impairment, the daily dose of Darifenacin should not exceed 7.5 mg.